In the Last 7 days there's been 28 influencers like BioWorld and NatureBiotech, discussing topics such as #genetherapy, #COVID19and #PharmaScrip.



Trends


Top hashtags

Top influencers

  BioWorld
  NatureBiotech
  PharmaScrip
  GENbio
  Gene_Medicines
  biospace
  matthewherper
  pharmaphorum
  CellCultureDish

Top sources

source img bioworld.com
source img biospace.com
source img genengnews.com
source img scrip.pharmaintelligence.informa.com
source img pharmaphorum.com
source img endpts.com
source img podcasts.apple.com
source img fiercebiotech.com
source img labiotech.eu

News

The top 10 takeover targets in biopharma

On Oct 19, 2020
@FierceBiotech shared
M&A activity still looks fairly lively in 2020 despite a somewhat subdued start as the industry adapted to the looming coronavirus pandemic. https://t.co/u7ZpDjIr71
Open

Most if not all large-cap pharma and biotech companies are still in need of business development as they work to rebalance their operations. Cancer, rare disease, and to a lesser extent central nervous system players are targets that match up most closely with prospective buyers.

www.fiercebiotech.com
On Oct 19, 2020
@FierceBiotech shared
M&A activity still looks fairly lively in 2020 despite a somewhat subdued start as the industry adapted to the looming coronavirus pandemic. https://t.co/u7ZpDjIr71
Open

The top 10 takeover targets in biopharma

The top 10 takeover targets in biopharma

Most if not all large-cap pharma and biotech companies are still in need of business development as they work to rebalance their operations. Cancer, rare disease, and to a lesser extent ...


On Oct 20, 2020
@Labiotech_eu shared
Choosing the right #business model can be essential for a young #biotech company to succeed. #Strategy consultant Robert Thong gives us his expert insight on the advantages of each model and discusses in which situations each of them is most suitable. 🧠 https://t.co/S5w3jSI45b
Open

Everything You Need to Know About Biotech Business Models

Everything You Need to Know About Biotech Business Models

What's my business model? Who do I partner with? How do I scale up? These are typical strategic questions a young biotech will regularly face.

On Oct 19, 2020
@GENbio shared
Rentschler Biopharma and [email protected]_bio Ink Leap-In Transposase Licensing Deal. Read more: https://t.co/E860euZYTp #biopharma #bioprocessing https://t.co/FHJOVqy4rp
Open

Rentschler Biopharma and ATUM Ink Leap-In Transposase Licensing Deal

Rentschler Biopharma and ATUM Ink Leap-In Transposase Licensing Deal

Rentschler plans to integrate the technology into its in-house process with what it calls a fast, cost-effective, and stable platform.

On Oct 16, 2020
@GENbio shared
[email protected] raises $30 M in Financing. The new funding will help take their manufacturing platform to the market that delivers solutions to address the clinical and commercial manufacturing needs of cell and #genetherapy developers. Learn more: https://t.co/3KDStJHa7A https://t.co/FryA7W3zq3
Open

Ori Biotech Raises $30 Million in Financing

Ori Biotech Raises $30 Million in Financing

 Funds will be used to advance innovation in cell and gene therapy manufacturing.

On Oct 16, 2020
@CellCultureDish shared
See what biotech news you missed this week in the Dish's weekly wrap up - https://t.co/Ae52BMIY95
Open

The Dish’s Weekly Biotechnology News Wrap Up – October 16, 2020

The Dish’s Weekly Biotechnology News Wrap Up – October 16, 2020

0 0 0 Total0 This week’s headlines include: U.S. government signs deal to make more COVID-19 vaccine components, Eli Lilly pauses study of COVID-19 treatment over safety concerns, Pfizer to ...

On Oct 18, 2020
@NatureBiotech shared
RT @UMassMedical: Guangping Gao, PhD, & #NobelPrize2020 winner Jennifer Doudna are both on @NatureBiotech's list of top translational biotech researchers for 2019. The #genetherapy pioneer & director of @UMMSGeneTherapy was on the 2018 list too. https://t.co/DQLXMsOuro @nresearchnews #UMassMedNews
Open

Guangping Gao makes list of Nature Biotechnology Top 20 translational researchers

Guangping Gao makes list of Nature Biotechnology Top 20 translational researchers

An influential scientific journal’s list of top translational biotech researchers for 2019 includes Guangping Gao, PhD. Rankings are based on total patents for the year, among other ...

On Oct 16, 2020
@biospace shared
Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry #biospace #lifesciences #biotechnology #pharmaceuticals #3D #Bioprinting https://t.co/LHXSLKg1BA
Open

Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry

Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry

By using naturally-derived scaffolds, human cells and other biocompatible materials, 3D bioprinting has ushered in opportunities for researchers to design, print and optimize patient ...

On Oct 13, 2020
@LabRoots shared
A consistent and uniformly glycosylated product is key in biotherapeutics manufacturing. Now, you can select clones with maximum yield then glycosylate it by in vitro glycoengineering (IVGE) resulting in a complete and consistent end product. https://t.co/2NGiOPimiB https://t.co/Z8tYVEubF6
Open

In vitro glycoengineering - Suitability for BioPharma manufacturing

In vitro glycoengineering - Suitability for BioPharma manufacturing

Introduction The importance of Fc glycosylation of monoclonal antibodies (mAbs) with regard to biological activity is widely discussed and has been investi | Drug Discovery And Development

On Oct 19, 2020
@matthewherper shared
Wait it's a cancer drug? @endpts makes a curious find on Calico: https://t.co/5gUetAPsAV
Open

Super-secretive anti-aging biotech Calico tees up the first visible clinical trial of an experimental drug. And it’s for cancer?

Super-secretive anti-aging biotech Calico tees up the first visible clinical trial of an experimental drug. And it’s for cancer?

Over the past 7 years, Calico has been so much more than your average, run-of-the-mill secretive biotech players. It’s a riddle, wrapped in a mystery, inside an enigma, to repurpose an old ...

On Oct 13, 2020
@biospace shared
Biopharma Update on the Novel Coronavirus: October 13 #biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine https://t.co/AuDpHnjb3t
Open

Biopharma Update on the Novel Coronavirus: October 13

Biopharma Update on the Novel Coronavirus: October 13

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.

Browse topics

Get updates live! Follow us on

Choose your newsletters

On Oct 19, 2020
@BioWorld shared
SPACs are hot this year, offering alternative route to public market https://t.co/kIOzinvqhe
Open

SPACs are hot this year, offering alternative route to public market

SPACs are hot this year, offering alternative route to public market

Even though the appetite for biopharma IPOs this year has been voracious with no signs of a slowdown anytime soon, companies also have a potentially faster route to the public market using ...

On Oct 15, 2020
@pharmaphorum shared
Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion. https://t.co/tAynpX2hpl
Open

Lilly to buy private biotech Disarm Therapeutics for up to $1.36bn

Lilly to buy private biotech Disarm Therapeutics for up to $1.36bn

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

On Oct 19, 2020
@Gene_Medicines shared
RT @_timos_: Gene&Cell Therapy >> CAR-plus: Irish biotech recruits Kite alum Chris Nowers to prep dual-targeting NK cell therapy for the clinic: Soon after Chris Nowers left Cell Medica — freshly rebranded Kuur Therapeutics — in… https://t.co/YDozwjv7Oz #lucidquest #genetherapy #celltherapy https://t.co/l9Rsj0FSAn
Open

CAR-plus: Irish biotech recruits Kite alum Chris Nowers to prep dual-targeting NK cell therapy for the clinic

CAR-plus: Irish biotech recruits Kite alum Chris Nowers to prep dual-targeting NK cell therapy for the clinic

Soon after Chris Nowers left Cell Medica — freshly rebranded Kuur Therapeutics — in February, the Kite Pharma alum was introduced to another cell therapy player. The basic idea of building ...

On Oct 15, 2020
@kiranshaw shared
RT @Bioconlimited: Catch @kiranshaw at the #GlobalTrendsFestival2020, sharing insights on why entrepreneurs must be risk-takers, her journey as a businesswoman, and unlocking India's potential. https://t.co/LrbI4QGw03
Open

Catch Kiran Mazumdar Shaw at the Global Trends Festival 2020, speak about unlocking India's suppressed potential

Catch Kiran Mazumdar Shaw at the Global Trends Festival 2020, speak about unlocking India's suppressed potential

Global Trends Festival is one of the world's most prestigious events which will be live from Oct 19-23. While nobel laureates, some of the biggest political

On Oct 14, 2020
@Regeneron shared
We’ve been named one of #AmericasMostJUST companies by @Forbes and @justcapital_ for our commitment to using our resources and expertise to make the world a better place. More on the #JUST100: https://t.co/7uCfrMZ9QD #ResponsibleRegeneron https://t.co/4k7j6Dckzi
Open

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Regeneron is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

On Oct 14, 2020
@BioWorld shared
Dyno sparks a $1.8B deal with Roche to develop CNS therapies https://t.co/esYP1SLAVq
Open

Dyno sparks a $1.8B deal with Roche to develop CNS therapies

Dyno sparks a $1.8B deal with Roche to develop CNS therapies

Privately held Dyno Therapeutics Inc., an early stage biotech company applying artificial intelligence to gene therapy, entered a collaboration and license agreement with Spark Therapeutics ...

On Oct 19, 2020
@jgi shared
ICYMI: "If diversity disappears, it’s never able to be recreated. We can recreate many different things, but we cannot recreate lost diversity." -Ben Shen @lab_shen @scrippsresearch in our @jgi Natural Prodcast #podcast at https://t.co/ToatOkjSMR. @lbnlbiosci @BerkeleyLab
Open

Natural Prodcast Episode 7: Ben Shen

Natural Prodcast Episode 7: Ben Shen

This is our conversation with Professor Ben Shen, from The Scripps Research Institute (TSRI) in Jupiter, Florida.

On Oct 14, 2020
@Gene_Medicines shared
RT @spark_tx: Through this novel collaboration with #AI innovator @Dyno_Tx and our colleagues at @Roche, we're one step closer to realizing the full potential of #genetherapy and addressing the unmet needs of more #patients: https://t.co/Nd9hBlR572 https://t.co/RZc3pP92JJ
Open

Dyno Therapeutics Enters Collaboration and License Agreement With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies

Dyno Therapeutics Enters Collaboration and License Agreement With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies

Dyno Tx Enters Collaboration and License Agreement with Roche to Develop Next-Gen AAV Gene Therapy Vectors for CNS Diseases, Liver-Directed Therapies

On Oct 13, 2020
@GENbio shared
RT @CRiverLabs: Senior business development director Olaf Stamm, Ph.D., discusses the importance of host cell proteins and effective analysis via @GENbio. https://t.co/vO4UOCOEC7
Open

Host Cell Protein Analysis Informs Risk Assessment

Host Cell Protein Analysis Informs Risk Assessment

Biologic-producing cells always pass along their own proteins. But which proteins? In what quantities? And to what effect? To answer these questions, look to sensitive assays and orthogonal ...

On Oct 19, 2020
@Gene_Medicines shared
RT @GENbio: Every new #biotech firm hopes to succeed like Genentech, the original biotech startup. Today, several new firms are focused on #genetherapy challenges such as vector selection and manufacturing. Read [email protected]'s latest in our October issue:https://t.co/C750VmGsrQ https://t.co/g3O3VqBolE
Open

Gene Therapy Startups Extend Biotech’s Legacy

Gene Therapy Startups Extend Biotech’s Legacy

Every new biotech firm hopes to succeed like Genentech, the original biotech startup. Today, several new firms are focused on gene therapy challenges such as vector selection and ...

On Oct 16, 2020
@BioWorld shared
Second inactivated SARS-CoV-2 vaccine candidate from China reports clinical data https://t.co/r6AUsppL9f
Open

Second inactivated SARS-CoV-2 vaccine candidate from China reports clinical data

Second inactivated SARS-CoV-2 vaccine candidate from China reports clinical data

DUBLIN – The Lancet Infectious Diseases has published the first clinical data on BBIBP-CorV, an inactivated whole virus vaccine directed against SARS-CoV-2. The early stage phase I/II study ...